Enhertu recommended for breast cancer EU approval
27 June 2022 07:05 BST Enhertu recommended for approval in the EU by CHMP for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen Recommendation based on DESTINY-Breast03 trial results showing AstraZeneca and Daiichi Sankyo's Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-